Clinical Trials Browser

Completed × Breast Neoplasms × Cetuximab × Clear all

Breast Neoplasms

NCT02124148 2020-04-01

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Phase 1 Completed

167 enrolled

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00622674 2017-12-02

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00232505 2017-06-28

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Phase 2 Completed

112 enrolled 13 charts

Breast

Breast Neoplasms

NCT00275041 2016-12-13

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

21 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00633464 2016-03-10

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Phase 2 Completed

79 enrolled 15 charts

Breast

Breast Neoplasms

NCT00600249 2014-03-20

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Phase 2 Completed

35 enrolled

Breast

Breast Neoplasms

NCT00463788 2014-02-13

BALI-1

Phase 2 Completed

181 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Clinical Trials

ICE

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

BALI-1